Pharmacokinetics and innovative therapeutics

Dr Ben Allal

Therapeutic management in cancerology in the twenty-first century must allow the personalization of treatments and doses of anti-cancer drugs in the best possible balance of efficacy and toxicity.

We have the analytical expertise and four triple quadrupole U-HPLC-MS/MS systems applied to the quantification of drugs or innovative molecules in biological media in collaboration with academic teams (e.g. Dendrogenin A and OCDO in collaboration with team 12) and industry (new molecules in clinical development). The first clinical trials of a drug in humans allow us to study its fate in the body (pharmacokinetics). We carry out the assays and their interpretation corresponding to these studies. Our analytical resources also allow us to carry out the work of the other areas of the team, particularly pharmacokinetic and modelling studies. As an example, we are developing the assay of venetoclax and its metabolite of which would allow better monitoring of this treatment.

Financing :

ANSM, PHRC, institutional (region -DDA coll Eq 12), pharmaceutical industry

Key words :

• Innovative molecules,
• Analytical,
• Pharmacokinetics,
• Individualisation of treatments

 Illustration :

Détermination des fragments clés du métabolite M27 du Venetoclax dans des plasmas de patients M27 Venetoclax metabolite Mass Spec fragmentation parameters determination in patient plasma / Determination of key fragments of Venetoclax metabolite M27 in patient plasma M27 Venetoclax metabolite Mass Spec fragmentation parameters determination in patient plasma